Baxdela Approval History
FDA Approved: Yes (First approved June 19, 2017)
Brand name: Baxdela
Generic name: delafloxacin
Dosage form: Tablets and Injection
Company: Melinta Therapeutics
Treatment for: Skin and Structure Infection
Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
Development History and FDA Approval Process for Baxdela
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.